First-Line Hormone Therapy for Metastatic Breast Cancer in Post-Menopausal Women

The choice of first-line hormone therapy for a post-menopausal woman diagnosed with metastatic breast carcinoma depends on targeting the specific hormonal environment driving cancer growth.

Anastrozole Efficacy in Post-Menopausal Patients

• Anastrozole is an Aromatase Inhibitor (AI). In post-menopausal women, the primary source of estrogen is not the ovaries but the conversion of androgens in peripheral tissues, a process mediated by the enzyme aromatase.
• Aromatase Inhibitors like Anastrozole effectively block this enzyme, significantly reducing circulating estrogen levels. This deprivation starves hormone-sensitive (Estrogen Receptor-positive) breast cancer cells, making it a standard and highly effective first-line treatment for this patient group.

Evaluation of Other Options

• Tamoxifen: While an effective endocrine therapy, it's an Estrogen Receptor Modulator. It is often considered first-line for pre-menopausal women or may be used after AI therapy in post-menopausal women. Aromatase inhibitors are generally preferred as initial therapy for hormone-sensitive metastatic disease in post-menopausal individuals.
• Ovarian suppression by surgery: This directly targets ovarian estrogen production. It is relevant only for pre-menopausal women and not applicable to post-menopausal women, as their ovaries are no longer the primary source of estrogen.
• Antiprogestins: These drugs block the action of progesterone. While sometimes used in specific cancer contexts, they are not a standard first-line hormone therapy for metastatic breast carcinoma in post-menopausal women.

Therefore, Anastrozole represents the appropriate first-line hormone therapy choice.